Compare ADMA Biologics Inc (ADMA) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Ross Stores, Inc. — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Ross Stores, Inc. trades at $216.37 (market cap $68.86B). The key difference: Ross Stores, Inc. is far larger — about 32.3× ADMA Biologics Inc's market cap, and Ross Stores, Inc. pays a 0.83% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ROST | |
|---|---|---|
Market Cap | $2.13B | $68.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $240.13 |
52-Week Low | $7.60 | $127.59 |
Enterprise Value | $2.20B | $69.45B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Ross Stores (ROST) trades at $214.67, up 0.58% today, with strong fundamentals including 9.74% net income margin and 38.98% ROE. Recent earnings beats and a consensus price target of $259.00 suggest upside potential. Technicals are bearish near-term, but positive news highlights robust sales growth and expansion. Cash flow trends show volatility, with 2025 net cash flow negative but projected to rebound in 2026.
Outlook is positive driven by earnings momentum and store expansion, but risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is bullish with 64% buy ratings, supporting a growth-oriented view for investors seeking retail exposure with solid profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
